If you are not able to view this e-mail properly, please click here to view it online
World Pharma Today Maqazine
World Pharma Today Linkedin Page World Pharma Today Facebook Page World Pharma Today Twitter Page Weekly Newsletter
Click here to subscribe to our Magazine
The  Health Industry Summit (tHIS) 2017
Top Latest Press Releases
Medical fair thailand 2017

Medical fair thailand 2017 reflects the bullish growth of the Medical industry in the region

This year edition of MEDICAL FAIR THAILAND is set to be its biggest yet with more than 700 international exhibitors expected. 17 national and country pavilions will present more than 5,000 state-of-the-art medical and healthcare products...


Inovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Clinical Trial

Inovio Pharmaceuticals, Inc. announced preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine...


LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program

The Lead Discovery Center GmbH Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism.

Eyevensys receives French regulatory approval to advance EyeCET platform

Eyevensys receives French regulatory approval to advance EyeCET platform

Eyevensys, a private biotechnology company developing its proprietary EyeCET platform, the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address ophthalmic diseases.


Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease

Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity...


Neurocrine Announces FDA Approval of INGREZZA TM Capsules

Neurocrine Biosciences, Inc. announced that the U.S. FDA has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).INGREZZA, a novel, selective vesicular monoamine transporter...


For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here


For the latest visit: www.worldpharmatoday.com

World Pharma Today